JAK2 Gene, V617F Mutation, Quantitative (INACTIVE as of 05/17/21: Refer to 3003751 in the May Hotline)
Use to quantitate JAK2 V617F allele frequency from peripheral whole blood. Aids in risk stratification and therapeutic monitoring of JAK2 V617F mutation positive myeloproliferative neoplasms.
Polymerase Chain Reaction
DNA isolation: Sun-Sat
Assay: Mon, Wed, Fri
New York DOH Approval Status
Lavender (EDTA). Also acceptable: DNA extracted by CLIA certified lab.
Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL).
Extracted DNA: Transport 40uL DNA with at least 50 ng/uL concentration (Min: 40uL). Transport DNA in a tissue transport kit (ARUP Supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.
Plasma, serum, FFPE tissue blocks/slides, or frozen tissue, bone marrow, DNA extracted by a non-CLIA lab. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.
Ambient: 24 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Extracted DNA: Ambient: 1 month; Refrigerate: Indefinitely; Frozen: Indefinitely
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0040167||JAK2 Gene, V617F Mutation, Quantitative||53761-3|
- BCR-ABL1-negative tesing
- Classic BCR-ABL1-negative MPN testing
- MPN JAK 2
- mutant JAK 2 V617F allelic burden